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Abstract
Background—Adverse drug events (ADEs) affect millions of patients annually and place a 
significant burden on the healthcare system. The Food and Drug Administration (FDA) has 
developed patient safety information for high-risk medications that pose serious public health 
concerns. However, there are currently few assurances that patients receive this information or are 
able to identify or respond correctly to ADEs.
Objective—To compare the effectiveness of the Electronic Medication Complete 
Communication (EMC2) Strategy to promote safe medication use and reporting of ADEs in 
comparison to usual care.
Methods—The automated EMC2 Strategy consists of: 1) provider alerts to counsel patients on 
medication risks, 2) the delivery of patient-friendly medication information via the electronic 
health record, and 3) an automated telephone assessment to identify potential medication concerns 
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or ADEs. The study will take place in two community health centers in Chicago, IL. Adult, 
English or Spanish-speaking patients (N=1,200) who have been prescribed a high-risk medication 
will be enrolled and randomized to the intervention arm or usual care based upon practice location. 
The primary outcomes of the study are medication knowledge, proper medication use, and 
reporting of ADEs; these will be measured at baseline, 4 weeks, and three months. Intervention 
fidelity as well as barriers and costs of implementation will be evaluated.
Conclusions—The EMC2 Strategy automates a patient-friendly risk communication and 
surveillance process to promote safe medication use while minimizing clinic burden. This trial 
seeks to evaluate the effectiveness and feasibility of this strategy in comparison to usual care.
Keywords
medication safety; health literacy; adherence
INTRODUCTION
Research has repeatedly demonstrated that patients lack essential information on how to 
safely take prescribed (Rx) medications.1,2 This lack of knowledge has been cited as a root 
cause of unintentional misuse and medication errors, which can lead to serious adverse drug 
events (ADEs).2,3 While the exact prevalence of medication errors and ADEs in ambulatory 
care is difficult to determine, nearly 4.5 million outpatient physician visits and 1 million 
emergency department admissions are attributed to ADEs annually.4,5 Estimates also 
indicate that among adults who take a medication and are seen in outpatient practices, up to 
25% experience an ADE over the course of a year.5,6
While most prescribed medications carry risks, approximately 400 drugs have been deemed 
by the Food and Drug Administration (FDA) to possess serious public health concerns, 
warranting a Risk Evaluation and Mitigation Strategy (REMS).7 Yet, few, if any, 
mechanisms exist to ensure and confirm that primary care patients receive and understand 
instructions for use, risk information, or instructions on proper actions to take in response to 
ADEs. Routine monitoring for the safety of patients who use higher-risk medications is also 
not presently possible. Instead, providers rely heavily upon patients to independently learn 
about their prescribed medication, identify ADEs, and seek medical support.6 Thus ADEs 
are often detected late, if at all, leaving patients at risk for further harm and less effective 
treatment. From a public health perspective, a more comprehensive method for detecting 
ADEs could provide new information on a medication's safety profile and inform the care of 
others who are also taking the medication.
To address these shortcomings, we developed the Electronic Medication Complete 
Communication (EMC2) Strategy, which seeks to ‘hardwire’ risk communication and 
surveillance of higher risk medications in primary care using health information 
technologies, specifically electronic health record (EHR) and interactive voice recognition 
(IVR) technology. Herein we provide an overview of the EMC2 Strategy and describe the 
methods and rationale for evaluating this approach in a randomized controlled trial (RCT) 
funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
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METHODS
The EMC2 Strategy
The EMC2 Strategy consists of several components designed to promote: 1) provider 
counseling on medication use, risks and benefits; 2) dissemination of understandable, 
actionable medication information to patients; and, 3) routine surveillance of medication use 
and risks in ambulatory care. To automate implementation and limit use of clinic resources, 
the EMC2 intervention takes advantage of EHR and IVR platforms to facilitate patient 
education and medication monitoring. Specifically, patients enrolled at an intervention site 
will be exposed to the EMC2 Strategy, which is comprised of the following key components 
(Figure 1):
1. Provider Medication Alert—When a provider places a new order or dose change for 
an existing prescription for a high-risk medication, an EHR-generated alert will notify the 
provider that the medication requires patient counseling. This alert will contain a brief 
description of the key risks or side effects that patients may experience while taking this 
medication; this information is directly derived from the FDA-approved Medication Guide 
for the medication. Providers will also be given the option of clicking on an html link within 
the alert to view the entire text of the Medication Guide if desired.
2. Automated Delivery of FDA Medication Guide + Summary—The medication 
order will automatically cue printing of: 1) the FDA-approved Medication Guide for the 
drug in question and 2) a 1-page, patient-friendly summary of the Guide (i.e. Medication 
Guide Summaries). These materials will be provided to patients with the After Visit 
Summary following the provider encounter. FDA Medication Guides are required to be 
distributed for the medications selected for this study at the point of dispensing; however, 
prior research indicates that pharmacies often fail to provide patients with this information.8 
To ensure that patients receive this essential information, it will be automatically printed and 
distributed to patients at the point of prescribing in primary care. Medication Guide 
Summaries were developed by our research team using health literacy ‘best practices’ to 
promote patient understanding of medication risks and instructions for use. A prior study 
conducted among 1,003 patients found that the Medication Guide Summaries significantly 
improved patients’ ability to retrieve and apply medication information.9
3. IVR Follow-Up Phone Assessment—Within 14 days after enrollment in the study, 
patients will receive a text message asking them to contact an automated telephone system. 
Calling this line will initiate an IVR call, which will last less than 5 minutes and asks 
patients to report whether they have: a) filled the prescription, b) are taking the medication, 
and c) have experienced side effects that are unique to the medication in question. The 
system also explores barriers to obtaining the medication for patients who had not yet done 
so and barriers to adherence for patients who report non-adherence. A second IVR call will 
be placed 4 weeks later to follow up with patients again, using a similar format and series of 
questions. Automated conversation systems have been used previously by members of our 
study team to improve clinical screening, counseling, and medication management.10
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4. Clinic Follow-up—The results of the IVR telephone assessment will be sent back to the 
EHR as patient-reported data in the form of a laboratory report. It will be routed to the 
prescriber of the high-risk medication for which the surveillance is being conducted. In the 
event that a serious concern is identified, the nature of the issue (e.g., non-adherence, 
patient-reported side effect, etc.) will be detailed in this report. Clinic staff will monitor 
reports and respond to any identified concerns by calling and counseling the patient. Clinics 
have tailored their protocol for responding to reports based upon the resources, needs, and 
staffing of the individual clinics.
Study Design and Aims
To evaluate the impact and scalability of the EMC2 Strategy, we are conducting a 2-arm 
RCT. The specific aims of this three-year trial are to: 1) test the effectiveness of the EMC2 
Strategy, compared to usual care, to improve a) patient understanding of medication risks, b) 
patient use of higher-risk Rx medications, and c) the detection of ADEs; 2) assess whether 
the EMC2 Strategy can reduce disparities in medication understanding and use by patient 
literacy level, English proficiency, and age compared to usual care; and, 3) evaluate the 
fidelity of the EMC2 Strategy to promote provider counseling, deliver patient Rx 
information, monitor understanding and use, and inform providers of potential harms. In 
addition to evaluating the effectiveness of the EMC2 Strategy, we will also: 1) explore 
patient, provider, and health system barriers to implementing the EMC2 Strategy, and 2) 
determine the cost of delivering the EMC2 Strategy in primary care from a health system 
perspective.
Setting
Study sites for this trial include two Federally Qualified Health Centers (FQHCs) affiliated 
with The Alliance, an EHR system user-community composed of safety net providers. The 
Alliance is an innovator and national leader in using health information technology among 
FQHCs. For this study, we are working specifically with Heartland Health Centers and Near 
North Health Centers; both are located in metropolitan Chicago and are Public Health 
Service 330-funded FQHCs with federal mandates to care for medically underserved areas. 
Patients are racially and ethnically diverse; most are low income. Study clinics share a 
common EHR platform (GE Centricity®), which is centrally hosted by The Alliance.
Study Medications
To select the higher-risk medications targeted for this study, we first identified which drugs 
requiring an FDA Medication Guide were most commonly prescribed at Alliance-affiliated 
clinics. As the EMC2 Strategy is designed to support patient adherence and continued safe 
use of higher risk medications in an ambulatory care setting, we then removed any 
medications that were poorly matched for the approach, for example, those that are available 
without a prescription, primarily prescribed ‘as needed’ (PRN), for short-term use only, or 
are administered directly to patients in a clinic. A total of 69 medications were selected for 
the study.
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Participants
We will recruit 1,200 patients from participating clinics into the study; recruitment is 
anticipated to begin in December 2016 and will continue for approximately two years. 
Eligibility criteria for the study includes: 1) age 21 years and older; 2) English or Spanish 
speaking; 3) self-reported responsibility for administering one's own medication; 4) having 
received a new or changed dose prescription for a study medication at the index clinic visit; 
and, 5) having one's own telephone or cell phone. Patients will be excluded if they have any 
severe, uncorrectable vision, hearing or cognitive impairments that would preclude study 
participation or consent.
The sample size for this study was based on comparisons of the primary outcome of 
medication knowledge between the two arms (i.e., usual care vs EMC2) at the 3-month 
interview. We expect participants in the usual care arm to score an average of 55.6 
(SD=28.4) based on a previous study testing comprehension of the FDA standard Med 
Guides to those to be used in this study.9 Enrolling 1200 participants and estimating 80% 
retention at the in-person follow-up interview (n=960, 480 per arm), we will have 80% to 
detect a minimum difference of 5.5 between the EMC2 and the usual care arm assuming a 
Type I error of 5%, assuming 100 patients per practice site enrolled at baseline and n=80 
available at 3 month follow-up. This effect size was calculated based on an independent t-
test with a variance inflation factor to account for the cluster randomized design. An intra-
class correlation coefficient (ICC) of 0.001 was used as we expect the clustering of practice 
site to have minimal influence on patient outcomes.
Randomization
As the EMC2 Strategy includes changes to healthcare delivery, the intervention itself is 
diffuse and patient randomization is not feasible. Therefore, randomization will occur at the 
practice location level. There are 12 practice locations affiliated with the two study 
community health centers; participating practice locations will be matched by patient 
volume and proportion of Spanish speakers at each location and one from each pair will be 
randomly assigned 1:1 to either intervention or control arms using a random number 
generator. All patients attending a practice location will subsequently be randomized to 
either intervention or control arms based upon the assignment of the practice that they attend 
for medical care. As such, blinding will not be possible.
As practice locations are randomized to either intervention or control arms, all patients (i.e., 
both study participants and non-participants) who visit an intervention clinic and receive a 
prescription for one of the study medications will automatically receive some EMC2 
components during their clinic visit (provider medication alert, Medication Guide + 
Summary). However, only those patients who then consent to participate in the study will be 
eligible to receive the remaining EMC2 components (IVR assessment, clinic follow-up) and 
to participate in evaluation activities. This randomization and recruitment process will 
ensure that recruited patients receive all in-clinic EMC2 components on the day they receive 
a new or changed dose prescription for a higher risk medication. It will also result in a 
trickle down of some components of the EMC2 Strategy being given to patients seen at an 
intervention practice site, but not enrolled in the study.
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Patients attending a usual care clinic will receive standard care. This is likely to include 
variable rates of physician counseling on medication safety and use and little, if any, follow-
up post-visit. Patients will also not receive a Medication Guide Summary or FDA-approved 
Medication Guide at the point of prescribing; however, by law they should receive the latter 
at the pharmacy at the point of dispensing.
Human Subjects Protection and Clinical Trial Registration
The Institutional Review Board (IRB) of Northwestern University, Boston University and 
participating community health centers approved all study procedures. The clinical trial is 
registered on clinicaltrials.gov [NCT02785458].
Recruitment and Data Collection
On a nightly basis, Research Assistants (RAs) at Northwestern University will electronically 
receive, via a secure platform, a list of patients who were prescribed a study medication that 
day at a participating community health center. RAs will call patients and invite them to 
participate in the EMC2 evaluation. After confirming patient eligibility and obtaining verbal 
consent, the RA will administer the baseline interview over the phone. Additional phone 
interviews will be conducted by RAs at approximately 4 weeks and 3 months post baseline 
to capture study outcomes. Study data will be collected and managed using REDCap 
electronic data capture tools hosted by the Northwestern University Clinical and 
Translational Sciences (NUCATS) Institute.11
Measurement
Patient outcomes include: 1) knowledge of an Rx medication's benefits and risks; 2) 
medication use (proper use, medication adherence); and, 3) reporting of ADEs. We will also 
collect data on literacy level, English proficiency, and age. Additionally, we will examine: 4) 
fidelity outcomes that assess how reliably intervention components were delivered and 
received by patients, and 5) the costs of the intervention.
Medication Knowledge—Medication-specific knowledge measures have been created for 
each high-risk medication. Similar items are standard across medications, related to general 
use, risks and benefits, and side effects. Correct answers are tailored to the available content 
included in each Med Guide Summary, as done previously by our team.12 Medication 
knowledge will be assessed at baseline, 4 weeks and 3 months.
Medication Use—We will assess medication use by three domains: fill, proper use, and 
adherence. Fill will be assessed by patient self-report (yes/no) of having obtained the 
medication from the pharmacy. Proper Use (yes/no) will be assessed by asking patients to 
report the correct dose (amount of medication taken each time), frequency (times per day), 
and total amount per day taken for each high risk medication prescribed; all must be 
answered correctly for it to be considered proper use. Finally, adherence will be measured as 
the self-reported number of missed doses within the past 4 days and via a telephone-based 
pill count using established guidelines (pill form medications only).13 Medication use will 
be assessed, where applicable, at baseline, 4 weeks and 3 months.
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Reporting of ADEs—During the 3-month interview, patients will be asked to report if 
they have experienced any side effects from their medication since it was prescribed (yes/
no). If they respond yes, they will be asked to provide details on the side effect experienced. 
Two pharmacists will independently review all self-reported side effects to determine 
whether these symptoms could reasonably be linked to one of the prescribed high-risk 
medications. Subsequently, patients will be asked a series of targeted questions to determine 
if they experienced any side effects specifically identified on the FDA Medication Guide as 
being associated with the medication in question. We will then ask patients whether side 
effects were reported to their healthcare provider (yes/no) or resulted in a clinic visit, 
emergency room visit or hospitalization (yes/no). When possible, RAs will review medical 
records to determine if reported side effects and/or events were documented in the patient's 
chart.
In addition to investigating the effectiveness of the intervention, we will also evaluate the 
fidelity of the EMC2 Strategy to promote provider counseling, deliver patient Rx 
information, monitor understanding and use, and inform providers of potential harms. 
During the baseline interview (1-3 days post index clinic visit), we will ask patients (yes/no) 
whether a provider counseled them on the medication purpose, risk, and benefit. We will 
also ask the Health Literacy supplemental items of the Consumer Assessment of Health 
Providers Survey (CAHPS) to evaluate the extent and quality of provider verbal counseling 
on Rx medications.14 At baseline, we will also collect EHR data to determine whether the 
Med Guide Summary and FDA Medication Guide were printed along with intervention 
patients’ after-visit summaries and will ask patients in both arms to report whether they 
received any written medication information from their provider. Finally, at 3 months post 
baseline, we will collect data from the IVR system and EHR to determine whether IVR calls 
were completed by patients, whether responses warranted clinic follow-up and counseling, 
and whether this follow-up was received by patients.
Post-trial, qualitative interviews and/or discussion groups with providers, clinic staff, and 
patients will explore patient, provider, and health system barriers to implementing the EMC2 
Strategy. We will also assess the financial costs of running the EMC2 Strategy, including 
printing (printer ink, paper, staff time) and programmer time to develop and maintain the 
EHR and IVR platforms, to determine the cost of delivering the EMC2 Strategy in primary 
care from a health system perspective.
Data Analysis Plan
The proposed trial uses a cluster-randomized design where the practice location is the unit of 
randomization. We will randomize 12 locations to two arms (usual care, EMC2) resulting in 
6 per arm. Locations will be matched by total number of patients eligible for the study as 
well as proportion of Spanish speaking patients, with one location from each pair 
randomized to each arm. We will accrue ~100 patients per location, on average, and 
conservatively anticipate ≥80% retention at 3-month follow-up. These estimates result in 
1200 participants recruited with an anticipated 960 patients (480 per arm, 80 per location) 
available for primary data analysis.
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Medication knowledge associated with high risk medications is the first primary outcome of 
interest for Aim 1, and will be analyzed as a score ranging from 0-100 reflecting the percent 
of items correct for each medication. Medication use outcomes (proper use, adherence) and 
detection of ADEs are secondary outcomes of interest. Associations between the outcomes 
and potential confounders at the patient (socio-demographic characteristics, comorbidities, # 
and type of medications taken, previous history with side effects, literacy, and primary 
language) and medication (drug type, route of administration) levels will be examined. We 
intend to use generalized linear mixed models (GLMM) to analyze the data, which can 
handle data that is missing at random (MAR). Additionally, we will examine rates of 
missing data, and determine if there are any discernible patterns using GLMMs with a logit 
link function to predict the presence of missing data. Should we find significant predictors, 
we will use multiple impute methods and present results as secondary analyses.
To account for the correlated nature of the data from participants at the same practice and 
multiple observations per patient, we will use GLMMs for analyses of all data, specifying 
identity link for continuous and the logit link for binary outcomes using PROC GLIMMIX 
in SAS (v.9.4). Treatment assignment by time will be the independent variable of primary 
interest and modeled as a fixed effect and practice location as a random effect, with 
additional subject statement to model correlations within patient. We will also include fixed 
effects for any potential confounding covariates noted in the descriptive studies. For all 
GLMM analyses we will report point estimates and 95% confidence intervals, and the extent 
to which random effects suggest correlation of outcomes within practice location. 
Additionally, we will estimate the ICCs for all outcomes to be used in future studies.
For Aim 2, we will repeat all GLMM analyses described above, but with the inclusion of a 
fixed effect for participants’ literacy defined as limited vs. adequate. We will formally test 
for differences in intervention effects according to literacy by including a literacy-
intervention interaction term. Statistically significant interaction terms (p<0.05) will indicate 
that the disparities in understanding between the intervention and usual care group vary by 
literacy level. Similar analyses will be used to test for interactions of intervention effects by 
age and English proficiency.
Following completion of enrollment, we will determine the extent to which the intervention 
was implemented as planned in the intervention arm. We ask patients whether they received 
the Med Guide Summaries and the post-visit IVR calls and will inquire about provider 
counseling on medication use and benefits. Since counseling behaviors and receipt of 
educational materials will be assessed in both arms, we will be able to determine whether 
our intervention promoted provider counseling and delivery of patient Rx information using 
t-tests, Wilcoxon Rank-Sum, or χ2 tests, as appropriate.
A combination of patient focus groups and individual interviews with prescribers and nurses 
will be conducted to understand in detail any barriers to implementation of the EMC2 
Strategy. Preliminary findings from fidelity analyses highlighting process outcomes and 
possible ‘voltage drops’ in implementation will be explored further in these interviews. Our 
conceptual framework will guide discussions and interviews, along with Normalization 
Process Theory (NPT).15-17 NPT follows sociological principles pertaining to the 
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implementation of innovations into practice. It takes the worldview that multifaceted 
interventions are often needed, and that implementation and integration often depends on: 
the work (tasks to be completed), who is responsible, how it impacts current practice and is 
understood by an organization. Suggestions for further improvement of the strategy will be 
solicited. Discussions will be audio-recorded and transcribed for thematic analyses.18 
Responses will be organized and summarized by provider/patient and component.
We will directly measure and assess the provider perspective costs of developing and 
running the EMC2 Strategy. Specifically, we will estimate the incremental cost of the 
intervention relative to usual care from the perspective of the Alliance and each FQHC 
implementing this process and tools. The primary costs of running the EMC2 Strategy 
involves the limited expenses around printing (printer ink, paper, staff time) as a result of 
generating new medication information with after-visit summaries. However, we will 
include estimates for minimal programming maintenance, for both GE Centricity EHR and 
the IVR system, and will test the sensitivity of results to changes in the maintenance 
requirements in terms of programmer hours. We also will separately track development costs 
for software and other programming requirements based on programmer hours. Staff/
programmer costs will be measured using tracked time spent on the intervention and wage 
estimates. We will test the sensitivity of operational costs to different assumptions about the 
potential use of variable staff using different salaries but assuming the same proficiency in 
terms of time required. Further, we will assess the sensitivity of estimates to different 
proficiency levels that could arise from learning by doing.
DISCUSSION
A risk communication and surveillance strategy is needed in primary care to ensure that 
patients are adequately informed about medication risks and are taking medications safely. 
To date, most initiatives to reduce ADEs have focused exclusively on physician prescribing 
practices.19 Yet most ADEs do not result from poor prescribing decisions, but from side 
effects experienced from an appropriately prescribed drug.19 As many as half of ADEs can 
be detected and mitigated at an early stage, making opportunities for amelioration up to 2.5 
times as likely as opportunities to prevent ADEs through better prescribing.6,19,20
The EMC2 Strategy was devised to leverage EHR and IVR technologies to: 1) prompt and 
guide provider counseling; 2) automate the delivery of Medication Guides and patient-
friendly medication information at prescribing; 3) engage patients post-visit to confirm that 
they have sufficient information and are using medications properly; and, 4) activate the 
clinical team to help patients overcome any barriers to safe medication use. Overall, the 
strategy should enhance patient education on risks and benefits of medications and provide 
better opportunities for monitoring patient medication use in ambulatory care. As 37% of 
ameliorable ADEs have been attributed to patients not informing their provider of signs and 
symptoms, providing more opportunities for patients to report potential ADEs to providers is 
a crucial first step towards promoting medication safety.6,19
There are strengths and limitations to this study that should be noted. While multiple 
practice locations and community health centers are serving as sites for the study, all are 
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located in the Chicago metropolitan area. Results may not be generalizable to rural 
populations or those living in different geographic regions. Additionally, many study 
outcomes, such as medication adherence and ADEs, are difficult to measure. This study will 
rely upon patient self-report for these outcomes, which is subject to recall bias. Validated 
scales and measures are being used to minimize this concern. In terms of strengths of the 
study, we are testing the EMC2 intervention in resource-constrained FQHCs among 1,200 
English and Spanish-speaking patients; this will help determine the feasibility of 
implementing the strategy in other community health clinics for low-income, diverse patient 
populations. This study is also strengthened by our post-trial investigations, which will 
explore the barriers and facilitators to implementing the EMC2 Strategy and will also help 
determine its cost-effectiveness. These factors are often not assessed in randomized 
controlled trials and can be vital to dissemination and implementation efforts, should the 
intervention be shown to be effective.21
ADEs affect millions of patients each year and place a significant burden on the U.S. 
healthcare system.4,20 A risk communication and surveillance strategy is needed to assure 
that patients obtain their medications, know how to take their medications, can identify and 
properly respond to ADEs, and are given a chance to communicate this information to 
providers. This study aims to ‘hardwire’ this process into normal clinical practice through 
provider reminders to counsel on high-risk medications, patient-friendly medication 
information, automated follow-up phone assessments, and activation of the clinical team to 
address medication issues. If proven effective, the EMC2 Strategy could be implemented 
across the nation–including clinics with limited resources that treat vulnerable patient 
populations–to support the safe use of high-risk medications in ambulatory care.
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Figure 1. 
Sequence of EMC2 Components
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